Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.782
AS - Asia 10.048
EU - Europa 6.348
SA - Sud America 1.772
AF - Africa 194
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 6
Totale 31.169
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.438
SG - Singapore 3.490
VN - Vietnam 1.943
HK - Hong Kong 1.826
CN - Cina 1.787
IT - Italia 1.469
RU - Federazione Russa 1.465
BR - Brasile 1.440
IE - Irlanda 918
DE - Germania 736
SE - Svezia 573
GB - Regno Unito 334
ID - Indonesia 219
UA - Ucraina 203
CA - Canada 194
AR - Argentina 149
IN - India 143
FR - Francia 141
KR - Corea 108
MX - Messico 99
FI - Finlandia 98
ZA - Sudafrica 93
BD - Bangladesh 92
JP - Giappone 85
NL - Olanda 82
AT - Austria 77
TR - Turchia 75
PL - Polonia 59
EC - Ecuador 54
PK - Pakistan 45
ES - Italia 42
IQ - Iraq 41
MA - Marocco 30
CO - Colombia 29
BE - Belgio 28
DK - Danimarca 28
PY - Paraguay 28
SA - Arabia Saudita 25
UZ - Uzbekistan 24
CL - Cile 21
PE - Perù 21
TW - Taiwan 19
CH - Svizzera 18
EG - Egitto 17
AU - Australia 15
CZ - Repubblica Ceca 15
AE - Emirati Arabi Uniti 14
KE - Kenya 13
TN - Tunisia 13
LT - Lituania 12
UY - Uruguay 12
MY - Malesia 11
DZ - Algeria 10
PH - Filippine 10
PT - Portogallo 10
VE - Venezuela 10
HN - Honduras 9
AZ - Azerbaigian 7
DO - Repubblica Dominicana 7
IL - Israele 7
IR - Iran 7
JM - Giamaica 7
JO - Giordania 7
KZ - Kazakistan 7
MN - Mongolia 7
RO - Romania 7
BG - Bulgaria 6
BB - Barbados 5
CR - Costa Rica 5
LB - Libano 5
BH - Bahrain 4
BO - Bolivia 4
GE - Georgia 4
KG - Kirghizistan 4
LV - Lettonia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
RS - Serbia 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BY - Bielorussia 3
ET - Etiopia 3
EU - Europa 3
HU - Ungheria 3
MM - Myanmar 3
MU - Mauritius 3
NG - Nigeria 3
SN - Senegal 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
GT - Guatemala 2
GY - Guiana 2
LK - Sri Lanka 2
MT - Malta 2
Totale 31.139
Salva come PNG Salva come JPEG
Città #
Singapore 2.039
Hong Kong 1.824
Ann Arbor 1.515
Fairfield 1.223
Ashburn 1.145
Dublin 900
Ho Chi Minh City 616
Wilmington 605
Woodbridge 518
Seattle 511
Hanoi 483
Chandler 474
Frankfurt am Main 473
Houston 464
New York 426
Dallas 405
Cambridge 390
Milan 370
Princeton 370
Santa Clara 357
Beijing 273
Hefei 273
Dearborn 272
Los Angeles 226
Jakarta 180
Moscow 166
Altamura 160
Nanjing 156
Jacksonville 150
The Dalles 148
Lawrence 139
São Paulo 133
Chicago 115
Seoul 104
Buffalo 100
Shanghai 98
Rome 96
Munich 87
Ottawa 80
San Diego 77
London 72
Haiphong 71
Andover 65
Da Nang 61
Nuremberg 60
Guangzhou 54
Tokyo 50
Johannesburg 49
Warsaw 48
Boardman 47
Dong Ket 46
Rio de Janeiro 43
Vienna 43
Shenyang 42
Council Bluffs 41
Hebei 41
Helsinki 41
Toronto 40
Ha Long 39
Mexico City 37
Can Tho 36
Stockholm 36
Fremont 35
Hải Dương 35
Nanchang 35
Biên Hòa 34
Denver 34
Salt Lake City 34
Atlanta 33
Brasília 33
Lappeenranta 33
Monza 33
Montreal 32
Quận Bình Thạnh 32
Phoenix 30
Jinan 29
Ninh Bình 27
Orem 27
Poplar 27
Brooklyn 26
Thái Nguyên 26
Elk Grove Village 25
Porto Alegre 25
Changsha 24
Jiaxing 24
Bắc Ninh 23
Columbus 23
Kent 23
Tianjin 23
Turku 23
Brussels 22
Norwalk 22
Tashkent 22
Amsterdam 21
Ankara 21
Bologna 21
Chennai 21
Tampa 21
Belo Horizonte 19
Bắc Giang 19
Totale 20.220
Salva come PNG Salva come JPEG
Nome #
Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases 475
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 417
Diagnostic delay in bronchiectasis: an Italian perspective 362
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 362
Early referral to palliative care services in patients with IPF: A tool to take a step forward 357
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 323
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 314
Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases 304
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 298
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 292
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 281
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 275
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 272
Janus-faced amiodarone-induced pneumopathy 256
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 254
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 254
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 250
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 248
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 242
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 240
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 240
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 233
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 228
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 218
A multidisciplinary approach to screen the post-COVID-19 conditions 213
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 212
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 212
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 210
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 208
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 208
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 204
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 199
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 198
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 197
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 196
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 193
Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 193
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 189
Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review 188
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 188
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 187
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 187
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 185
Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD 183
The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis 180
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study 180
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 179
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 179
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 179
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 176
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 175
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 174
Diagnosis of asthma and copd 169
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 169
Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis 168
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 161
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach 161
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 161
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 159
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 155
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 154
Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection 153
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 152
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 152
Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case 151
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 151
Interstiziopatia polmonare non classificabile o secondaria a connettivite indifferenziata. importanza e difficoltà di una diagnosi differenziale 149
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 149
Digital health technologies for improving the management of people with chronic obstructive pulmonary disease 147
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 147
Questionnaires May Help Pulmonologists for Referral of Patients With IPF to a Holistic Approach 146
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 144
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 144
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 144
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 144
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs 143
Sleep-Disordered Breathing and Chronic Respiratory Infections: A Narrative Review in Adult and Pediatric Population 143
Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia 143
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 142
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 141
Management of Idiopathic Pulmonary Fibrosis 140
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases 139
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 138
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 138
The Multiple Components of COPD 138
Cystic lung in sarcoidosis: Clinico-radiologic characteristic and evolution 137
Sarcoidosis: challenging diagnostic aspects of an old disease 137
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 136
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A case report 135
Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers 134
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 134
Guiding ILD management in systemic autoimmune rheumatic diseases 133
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 133
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 133
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 133
Update in chronic obstructive pulmonary disease 2006 132
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 132
Update in chronic obstructive pulmonary disease 2005 131
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 130
Pathophysiology of exacerbations of chronic obstructive pulmonary disease 130
Totale 19.302
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.631
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.631
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.465 0 0 0 0 0 234 206 286 146 233 155 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20257.621 400 1.168 430 326 609 308 546 218 687 1.115 586 1.228
2025/202610.329 2.499 1.593 1.480 2.077 1.812 868 0 0 0 0 0 0
Totale 32.193